Li Mei, Qin Zhi, Steen Erik, Terry Ann, Wang Bowen, Wohlfart Björn, Steen Stig, Arner Anders
Department of Clinical Sciences, Lund, Lund University, Lund, Sweden.
Igelösa Life Science AB, Lund, Sweden.
Front Cardiovasc Med. 2023 Feb 20;10:1105257. doi: 10.3389/fcvm.2023.1105257. eCollection 2023.
Stone heart (ischemic contracture) is a rare and serious condition observed in the heart after periods of warm ischemia. The underlying mechanisms are largely unknown and treatment options are lacking. In view of the possibilities for cardiac donation after circulatory death (DCD), introducing risks for ischemic damage, we have investigated stone heart in pigs. Following cessation of ventilation, circulatory death (systolic pressure <8 mmHg) occurred within 13.1 ± 1.2 min; and a stone heart, manifested with asystole, increased left ventricular wall thickness and stiffness, established after a further 17 ± 6 min. Adenosine triphosphate and phosphocreatine levels decreased by about 50% in the stone heart. Electron microscopy showed deteriorated structure with contraction bands, Z-line streaming and swollen mitochondria. Synchrotron based small angle X-ray scattering of trabecular samples from stone hearts revealed attachment of myosin to actin, without volume changes in the sarcomeres. Ca sensitivity, determined in permeabilized muscle, was increased in stone heart samples. An model for stone heart, using isolated trabecular muscle exposed to hypoxia/zero glucose, exhibited the main characteristics of stone heart in whole animals, with a fall in high-energy phosphates and development of muscle contracture. The stone heart condition was significantly attenuated by the myosin inhibitor MYK-461 (Mavacamten). In conclusion, the stone heart is a hypercontracted state associated with myosin binding to actin and increased Ca sensitivity. The hypercontractile state, once developed, is poorly reversible. The myosin inhibitor MYK-461, which is clinically approved for other indications, could be a promising venue for prevention.
石心(缺血性挛缩)是一种在心脏经历一段时间的热缺血后出现的罕见且严重的病症。其潜在机制大多未知,且缺乏治疗方案。鉴于心脏死亡后器官捐献(DCD)存在引入缺血损伤风险的可能性,我们对猪的石心现象进行了研究。停止通气后,在13.1±1.2分钟内出现循环死亡(收缩压<8 mmHg);再过17±6分钟后,出现了以心脏停搏、左心室壁厚度增加和僵硬为表现的石心。石心中三磷酸腺苷和磷酸肌酸水平下降了约50%。电子显微镜显示结构恶化,出现收缩带、Z线流和线粒体肿胀。基于同步加速器的石心小梁样本小角X射线散射显示肌球蛋白与肌动蛋白附着,肌节体积无变化。在通透化肌肉中测定的钙敏感性在石心样本中增加。使用暴露于缺氧/无糖环境的离体小梁肌构建的石心模型展现了全动物石心的主要特征,即高能磷酸盐下降和肌肉挛缩。肌球蛋白抑制剂MYK-461(mavacamten)可显著减轻石心状况。总之,石心是一种与肌球蛋白与肌动蛋白结合及钙敏感性增加相关的过度收缩状态。一旦形成,这种过度收缩状态很难逆转。临床上已批准用于其他适应症的肌球蛋白抑制剂MYK-461可能是一种有前景的预防手段。